Identification of new mutations in the TBX5 gene in patients with Holt-Oram syndrome
- W Heinritz1,
- A Moschik1,
- A Kujat1,
- S Spranger2,
- H Heilbronner3,
- S Demuth4,
- A Bier5,
- M Tihanyi6,
- S Mundlos7,
- C Gruenauer-Kloevekorn8,
- U G Froster1
- 1Institute of Human Genetics, University of Leipzig Medical Faculty, Leipzig, Germany
- 2Private Practice of Human Genetics, Bremen, Germany
- 3Institute of Clinical Genetics, Olgahospital, Stuttgart, Germany
- 4Private Practice of Human Genetics, Erfurt, Germany
- 5Institute of Clinical Genetics, Universitätsklinikum Carl-Gustav-Carus, University of Technology, Dresden, Germany
- 6Zala County Hospital, Department of Human Genetics, Zalaegerszeg, Hungary
- 7Institute of Medical Genetics, Charité, Campus Virchow, Berlin, Germany
- 8Department of Ophthalmology, Martin-Luther-University Halle-Wittenberg, Halle, Germany
- Correspondence to:
Professor Dr Med Ursula G Froster
Institute of Human Genetics, University of Leipzig Medical Faculty, Philipp-Rosenthal-Str. 55, 04103 Leipzig, Germany;
- Accepted 19 May 2004
Holt-Oram syndrome (HOS) (MIM 142900), first described by Holt and Oram in 1960, is characterised by malformations of the upper limbs involving mainly the pre-axial ray and variable cardiac defects, most of them septation defects. This autosomal dominant inherited condition occurs in approximately 1 in 100 000 live births and shows high penetrative and variable intrafamilial and interfamilial clinical expression.
The gene locus for HOS was mapped to chromosome 12q24.1. Mutations in the TBX5 gene (MIM *601620) were delineated as the underlying defect in HOS.1–5 TBX5 is a member of the T-box transcription factor family. It plays an indispensable role in development of heart and upper limbs during embryogenesis. To date there have been 34 different mutations at DNA level described in families with HOS; these mutations are spread over all the coding exons of the TBX5 gene.1–5
PATIENTS AND METHODS
The patients for our study were recruited by a circular letter to human geneticists, experts in dysmorphology, and child cardiologists throughout Germany, Austria, Hungary, and Switzerland. The participating colleagues were asked to summarise the clinical data of their patients (all presenting with a combination of variable congenital heart defects and upper limb malformations) in a standardised format. DNA samples of all patients and their first degree relatives were collected after informed consent. Genomic DNA was prepared from peripheral blood according to standard procedures. Primers for analysis of exon 2–9 of the TBX5 gene were designed as published by Basson and colleagues.1 The position of nucleotides was identified according to the GenBank sequence U89353.1.
Exons 2–9 of the TBX5 gene were amplified by polymerase chain reaction (PCR) in a 50 μl reaction volume containing 200 ng of genomic DNA, 1 × PCR buffer II, 0.2 mM deoxynucleotide triphosphate (dNTP), 2.5 mM MgCl2, 1 μl of each primer (10 pM), and 1 U AmpliTaq polymerase (Applera, USA). Cycling program on a GeneAmp PCR System 2400 (PE, USA) was as following: 95°C for 2 minutes, 30 cycles of 20 seconds at 95°C, 30 seconds at 60°C, 45 seconds at 72°C, and finally 7 minutes at 72°C. PCR products were analysed on 1.4% agarose gels, purified with the Qiaquick PCR purification kit (Qiagen, Germany), cycle sequenced by using the BigDye-DNA sequencing kit (Applera, USA), and analysed on an ABI Prism 377 DNA sequencer (PE, USA) according to the protocol of the manufacturer.
Among a total of 42 unrelated patients we found mutations in the TBX5 gene in nine patients (22%), four familial and five sporadic cases of HOS. The results of mutation analysis and the clinical data of the patients and their affected relatives are summarised in table 1.
The spectrum of identified pathogenic sequence variations includes three frameshift mutations and one nonsense mutation, which are predicted to lead to a truncated gene product causing HOS in the mutation carrier. Furthermore, we found one well known nonsense mutation (R279X) and one mutation, which could be detected in two unrelated families (Y136X). The last one was recently published as a special case report.4 Consanguinity between all families was excluded by extensive pedigree analyses. In two other patients new splice site mutations have been identified. The effects of these mutations are yet unknown, but they are suggested to cause HOS.
The mutational change in all cases was associated with different skeletal and heart anomalies (table 1). Carriers of mutations leading to a premature translational stop showed a severe phenotype of HOS. Patients IPM 1 and IPM 7, which carry the splice site mutations, showed a milder phenotype with only thumb anomalies and conductive heart failure and small atrial septal defects and ventricular septal defects respectively.
Mutations in the TBX5 gene spread over the entire coding region. Most of them are located within the highly conserved DNA binding T-box domain of the gene, spanning from amino acids 55–237. It was shown that the amino acids 1–54, which are not fully conserved, as well as the C-terminal residues 238–518 in the TBX5 protein, are required for effective DNA binding and regulation. This finding was reinforced by identification of mutations in these parts of the TBX5 gene in HOS patients.2
The mutation R279X can be suggested as a hot spot mutation in the TBX5 gene. In our study patient IPM 8, with a severe clinical manifestation of HOS, is a carrier of R279X. Altogether just five of all presently known mutations in TBX5 (S196X, T223M, R237Q, R237W, R279X) are responsible for about 50% of all cases of HOS.
Notably there is no evidence for a special genotype/phenotype correlation of nonsense or frameshift mutations within or outside the T-box domain.2 In contrast to this, a distinct mechanism of missense mutation effects in TBX5 was suggested. The position of missense mutations within the T box domain seems to be associated with phenotype expressions showing either predominantly heart defects (G80R,G169R) or limb anomalies (R237Q, R237W).1,3 To date 11 different missense mutations in TBX5 are known. In our study no missense mutations were detected.
The mutation in patient IPM 1 alters a highly conserved nucleotide at the 3′ acceptor splice site of intron 3. In most eukaryotic genes an adenine is located at position two of the 3′ intronic site. This mutation was not detectable in 50 control samples. Therefore, it can be presumed that the mutation produces an alternatively spliced protein which causes HOS in our patient.
For patient IPM 7, who is carrier of the mutation IVS7-3 C>G, we compared sequences of the TBX5 gene of various species and have found partial consent at the 3′ acceptor splice site of intron 7—for example in Mus musculus (NCBI, Acc.-No: NT_039312). The mutation seems to be responsible for HOS in this patient because it was not found in 50 control samples including both parents of IPM 7.
In HOS patients without mutations in TBX5 further investigations should comprehend proper methods to exclude gross deletions within the gene or chromosomal changes. The overall mutation detection rate in our cohort was as low as in other studies (22%). Reasons, such as clinical misdiagnosis, genetic heterogeneity of HOS, and mutations outside the TBX5 gene have to be considered. Investigation of other genes, which are primarily associated with congenital heart and limb defects—for example SALL4—may help to distinguish similarly appearing phenotypes.2